Dr. Birrer On The Ovarian Cancer Avastin Os Benefit

Dr. Birrer on the Ovarian Cancer Avastin OS Benefit

Dr. Birrer Discusses Recurrent Ovarian Cancer Treatment

Dr. Michael Birrer on Bevacizumab in Ovarian Cancers

Targeted Oncology

Dr. Birrer on the Approval Process in Ovarian Cancer

Dr. Birrer on Other Targets in Ovarian Cancer

Targeted Oncology

Dr. Birrer Discusses the GOG0218 and ICON7 Trials

Bevacizumab in Recurrent Ovarian Cancer

When to Add Bevacizumab for Recurrent Ovarian Cancer

Bevacizumab in Ovarian Cancer

ASCO 2018: Dr. Birrer on Practice-Changing Ovarian Cancer Studies

Michael Birrer Discusses Personalization of Ovarian Cancer Care

Bevacizumab’s Role in Recurrent Ovarian Cancer

Dr. Birrer on FDA Approval of Rucaparib in Ovarian Cancer

Avastin Delays Ovarian Cancer Disease Progression

Vital Options International

Dr. Birrer on PARP Inhibitors in Ovarian Cancer

Michael J. Birrer MD, PhD: Future of Ovarian Cancer Treatment: Personalized Medicine

Foundation for Women's Cancer

Dr. Burger on the Toxicity Profile of Bevacizumab in Ovarian Cancer

Intraperitoneal Chemotherapy and Ovarian Cancer

Dr. Birrer on PARP Inhibitors in Ovarian Cancer

Dr. Jason Konner Discusses Bevacizumab in Ovarian Cancer